CRBU - Caribou Biosciences, Inc. Stock Price, Fair Value and News

2.48USD+0.04 (+1.64%)Market Closed

Market Summary

USD2.48+0.04

Market Closed

1.64%

CRBU Stock Price

View Fullscreen

CRBU RSI Chart

CRBU Valuation

Market Cap

224.0M

Price/Earnings (Trailing)

-1.94

Price/Sales (Trailing)

6.76

EV/EBITDA

-1.92

Price/Free Cashflow

-1.97

CRBU Price/Sales (Trailing)

CRBU Profitability

EBT Margin

-307.31%

Return on Equity

-33.58%

Return on Assets

-28.33%

Free Cashflow Yield

-50.71%

CRBU Fundamentals

CRBU Revenue

Revenue (TTM)

33.2M

Rev. Growth (Yr)

-30.64%

Rev. Growth (Qtr)

-31.73%

CRBU Earnings

Earnings (TTM)

-115.3M

Earnings Growth (Yr)

-47.03%

Earnings Growth (Qtr)

-19.5%

Breaking Down CRBU Revenue

Last 7 days

7.8%

Last 30 days

53.1%

Last 90 days

-33.1%

Trailing 12 Months

-61.1%

How does CRBU drawdown profile look like?

CRBU Financial Health

Current Ratio

10.49

CRBU Investor Care

Shares Dilution (1Y)

47.18%

Diluted EPS (TTM)

-1.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	33.2M	0	0	0
2023	14.7M	0	34.2M	34.4M
2022	10.7M	13.4M	12.7M	13.9M
2021	12.2M	5.2M	8.0M	9.6M
2020	7.4M	9.1M	10.7M	12.4M
2019	0	0	0	5.8M

Get all data in R, Python etc through our Historical Stock Data APIs

About Caribou Biosciences, Inc.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

CEO	Dr. Rachel E. Haurwitz Ph.D.
WEBSITE	https://cariboubio.com
INDUSTRY	Biotechnology
EMPLOYEES	137

Caribou Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Caribou Biosciences, Inc.? What does CRBU stand for in stocks?

CRBU is the stock ticker symbol of Caribou Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Caribou Biosciences, Inc. (CRBU)?

As of Fri Jul 26 2024, market cap of Caribou Biosciences, Inc. is 223.99 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRBU stock?

You can check CRBU's fair value in chart for subscribers.

Is Caribou Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether CRBU is over valued or under valued. Whether Caribou Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Caribou Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRBU.

What is Caribou Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, CRBU's PE ratio (Price to Earnings) is -1.94 and Price to Sales (PS) ratio is 6.76. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRBU PE ratio will change depending on the future growth rate expectations of investors.